Across TCGA pan-cancer cohorts, HSD17B11 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated HSD17B11 data layer compared with 4 for mutation status and 5 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher HSD17B11 RNA is associated with better overall survival. In most high-consensus cancer types, elevated HSD17B11 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.
KIRC, ACC, and SKCM are the cancer types where HSD17B11 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.